| abstract |
The invention relates to novel pharmaceutical compositions for treating patients with hypertension, which use, as active ingredients, the second-generation angiotensin II receptor type 1 blocker eprosartan combined with the third-generation calcium antagonist lercanidipine. These active ingredients, eprosartan and lercanidipine, have proven, as single agents, to be more effective and to have less adverse effects and an increased tolerance compared to other, commercially available, hypertensives. The combination is produced in the form of immediate-release and sustained-release tablets, as well as a powder for a suspension, the latter composition being useful for certain states of patients whose physical state does not allow the ingestion of tablets or capsules and an intravenous injectable form has been developed for cases where immediate bioavailability is required. |